Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?

Anti-programmed cell death (PD)-1/PD-ligand 1 (L1) therapies have significantly improved the outcomes for non-small cell lung cancer (NSCLC) patients in recent years. These therapies work by reactivating the immune system and enabling it to target cancer cells once more. There is a general agreement...

Full description

Bibliographic Details
Main Authors: Emmanuel Acheampong, Isaac Spencer, Weitao Lin, Melanie Ziman, Michael Millward, Elin Gray
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
PD-L1
non-small cell lung cancer
circulating tumour cells
immunotherapy
Online Access:https://www.mdpi.com/2072-6694/11/7/920

Internet

https://www.mdpi.com/2072-6694/11/7/920

Similar Items